-

01:57:28 AM

GILD Stock News

GILD - Gilead Sciences, Inc.

02/02/23 4:05 PM

Nasdaq : GILD

dividends

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

Gilead Sciences, Inc. today announced that the company’ s Board of Directors has declared an increase of 2.7% in the company’ s quarterly cash dividend, beginning in the first quarter of 2023. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Gilead Sciences, Inc. is a biopharmaceutical company that has...

RHEA-AI

neutral

02/02/23 4:01 PM

Nasdaq : GILD

earnings

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2022.. This return to growth was driven by consistent and high quality commercial and clinical execution across our portfolio,” said Gilead’ s Chairman and Chief Executive Officer Daniel O’ Day.“ In HIV, Biktarvy gained market share in the U.S. as it has every quarter...

RHEA-AI

positive

02/02/23 9:00 AM

NYSE : GILD

Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC

Gilead Sciences Originally Published by Gilead Sciences Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer (TNBC). Addressing these barriers is critical to

RHEA-AI

neutral

02/01/23 8:35 AM

Nasdaq : GILD

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Gilead Sciences, Inc. awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity Oncology Grant™. “Gilead is committed to advancing health equity and supporting these vital patient advocacy organizations working to close gaps in breast cancer care,” said Deborah H. Telman, Executive Vice...

RHEA-AI

positive

01/30/23 9:00 AM

Nasdaq : ACLX, GILD

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Kite, a Gilead Company, and Arcellx, Inc., today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’ s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.

RHEA-AI

neutral

01/27/23 4:05 PM

Nasdaq : GILD

conferences

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences:. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. For more information on Gilead Sciences, please...

RHEA-AI

neutral

01/19/23 4:05 PM

Nasdaq : GILD

earnings

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

Gilead Sciences, Inc. announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of...

RHEA-AI

neutral

01/19/23 9:00 AM

NYSE : GILD

Decades-Long Effort to Enact Universal HIV Screening for Pregnant Women in Israel

Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September. "It was a long-awaited, emotional moment," says Hila, a member of the Israeli Society for HIV

RHEA-AI

neutral

01/12/23 9:00 AM

NYSE : GILD

covid-19

Meet Gilead’s COVID-19 Virus Variants Hunters

Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called "variant hunters." Their mission is to determine whether COVID-19

RHEA-AI

neutral

01/04/23 10:00 AM

NYSE : GILD

Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope

Gilead Sciences On any given day on the west side of Chicago, you might encounter something unexpected. Outside a retail store or hair salon, there may be a table providing breast cancer education and resources - and it's most likely staffed by Equal

RHEA-AI

negative

1 2 3 4 5 6 7 8 9 10 Next

GILD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.gilead.com
CeoDaniel O'Day
Security nameGilead Sciences, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees13600
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address333 Lakeside Dr
StateCalifornia
CityFoster City
Zip94404-1147
CountryUS
Phone16505743000

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.